Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Lowered by Zacks Research

Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 29th. Citigroup upgraded Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Wells Fargo & Company boosted their target price on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research note on Monday, January 5th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $3.70 price target on shares of Ironwood Pharmaceuticals in a research report on Thursday. Finally, Citizens Jmp lifted their price objective on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a “market outperform” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $4.93.

Ironwood Pharmaceuticals Price Performance

NASDAQ IRWD opened at $3.66 on Wednesday. The company has a market cap of $595.41 million, a P/E ratio of 28.15 and a beta of 0.17. The stock has a 50-day moving average of $4.28 and a two-hundred day moving average of $2.80. Ironwood Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.03). Ironwood Pharmaceuticals had a net margin of 8.11% and a negative return on equity of 13.72%. The business had revenue of $47.71 million during the quarter, compared to analysts’ expectations of $86.10 million. On average, analysts anticipate that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in IRWD. ProShare Advisors LLC raised its position in shares of Ironwood Pharmaceuticals by 9.6% during the 4th quarter. ProShare Advisors LLC now owns 36,315 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 3,170 shares in the last quarter. Integrated Wealth Concepts LLC increased its stake in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in shares of Ironwood Pharmaceuticals by 7.8% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 76,951 shares of the biotechnology company’s stock valued at $259,000 after buying an additional 5,598 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in shares of Ironwood Pharmaceuticals by 11.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 67,888 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 7,120 shares in the last quarter. Finally, Merit Financial Group LLC grew its position in shares of Ironwood Pharmaceuticals by 17.4% in the 3rd quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 7,232 shares during the last quarter.

Ironwood Pharmaceuticals News Roundup

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Management raised FY‑2026 revenue guidance to $450–$475 million and reiterated a strong outlook; LINZESS showed continued demand growth (11% EUTRx), which supports the higher top‑line guide. Ironwood Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst upgrade from Citizens JMP: price target raised to $10 with a “market outperform” rating — a significant bullish signal that can attract buyers and supports the stock’s rally. Benzinga
• Positive Sentiment: The company reiterated 2025 results achievement and provided investor materials (slide deck) and the conference‑call transcript, giving investors more transparency into drivers of the guide and product performance. Slide Deck
• Neutral Sentiment: Full Q4 earnings call transcript and presentation are available for review; these provide detail on cost structure, guidance assumptions and timing that investors will parse for clarity. Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations: EPS of ($0.01) vs. $0.02 expected and revenue of $47.7M vs. ~$86.1M consensus (revenue down ~47% YoY). The sizable miss and year‑over‑year revenue decline are the primary near‑term negative catalysts. Zacks: Q4 Earnings and Revenues Fall Shy
• Negative Sentiment: A Seeking Alpha piece downgraded the stock after reporting a pipeline setback and an extended timeline for Apraglutide, raising execution and timing risk for future growth catalysts. Seeking Alpha: Downgrading On Pipeline Setback

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.